Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 1.00 |
| ▸ | VEGFA | P15692 | 6/20 | 1.00 |
| ▸ | FLT1 | P17948 | 6/20 | 1.00 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 0.77 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.77 |
| ▸ | ASPH | Q12797 | 1/20 | 0.77 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.77 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.77 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.77 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.77 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921387 | 1.00 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL23501756 | 0.90 | EGLN1 (0.82) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3484916 | 0.90 | EGLN1 (0.82) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL19933469 | 0.90 | EGLN1 (0.82) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL22588827 | 0.90 | EGLN1 (0.81) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL20711144 | 0.89 | EGLN1 (0.80) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL22239387 | 0.89 | EGLN1 (0.80) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL24405118 | 0.88 | EGLN1 (0.79) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL15164149 | 0.88 | EGLN1 (0.80) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL24579666 | 0.88 | EGLN1 (0.78) | EGLN1VEGFAFLT1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| CN-111320577-B | Preparation method and application of pyridine amide | 广东东阳光药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4138825-A1 | TREATMENT OF VIRAL INFECTIONS, OF ORGAN INJURY, AND OF RELATED CONDITIONS USING A HIF PROLYL HYDROXYLASE INHIBITOR OR A HIF-ALPHA STABILIZER | Akebia Therapeutics Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4095127-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.